When these two peptides are combined, they are believed to act synergistically, supporting enhanced and more natural growth hormone secretion by targeting complementary pathways, which can contribute to overall revitalizing effects
[152] The same month, Lilly announced it would acquire Disarm Therapeutics and its experimental treatments for axonal degeneration, via SARM1 inhibitors, for $135 million plus up to another $1.225 billion based on regulatory and commercial milestones
doi: 10.3748/wjg.v20.i40.14821 54 WangYParlevlietETGeerlingJJvan der TuinSJZhangHBieghsVet al
And I think there probably will be quite a few once they've tried it
Klow is a four-peptide research blend that combines GHK-Cu, BPC-157, and TB-500, the same trio found in Glow, with a fourth peptide called KPV